Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zenas Biopharma Inc (ZBIO)

Zenas Biopharma Inc (ZBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,277,078
  • Shares Outstanding, K 57,371
  • Annual Sales, $ 10,000 K
  • Annual Income, $ -377,740 K
  • EBIT $ -383 M
  • EBITDA $ -383 M
  • 60-Month Beta -0.54
  • Price/Sales 123.12
  • Price/Cash Flow N/A
  • Price/Book 4.76

Options Overview Details

View History
  • Implied Volatility 108.94% (+11.86%)
  • Historical Volatility 75.16%
  • IV Percentile 39%
  • IV Rank 28.47%
  • IV High 189.19% on 01/02/26
  • IV Low 77.01% on 11/12/25
  • Expected Move (DTE 10) 1.04 (4.64%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 135
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 4,521
  • Open Int (30-Day) 3,352
  • Expected Range 21.29 to 23.37

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.35
  • Number of Estimates 3
  • High Estimate $-1.14
  • Low Estimate $-1.62
  • Prior Year $-0.80
  • Growth Rate Est. (year over year) -68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.20 +29.71%
on 03/27/26
26.98 -17.31%
on 03/10/26
-2.97 (-11.75%)
since 03/06/26
3-Month
15.80 +41.20%
on 01/08/26
29.55 -24.50%
on 02/17/26
+5.80 (+35.13%)
since 01/07/26
52-Week
6.11 +265.14%
on 04/09/25
44.60 -49.98%
on 12/24/25
+14.56 (+187.87%)
since 04/07/25

Most Recent Stories

More News
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million

WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed...

ZBIO : 22.36 (+0.45%)
Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

WALTHAM, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed...

ZBIO : 22.36 (+0.45%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 22.36 (+0.45%)
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results...

ZBIO : 22.36 (+0.45%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 22.36 (+0.45%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

NEW YORK , Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation...

ZBIO : 22.36 (+0.45%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Feb. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 22.36 (+0.45%)
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026

- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week...

ZBIO : 22.36 (+0.45%)
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 22.36 (+0.45%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 22.36 (+0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc'RIIb. Zenas BioPharma Inc. is based in WALTHAM,...

See More

Key Turning Points

3rd Resistance Point 24.08
2nd Resistance Point 23.39
1st Resistance Point 22.83
Last Price 22.36
1st Support Level 21.58
2nd Support Level 20.89
3rd Support Level 20.33

See More

52-Week High 44.60
Fibonacci 61.8% 29.90
Fibonacci 50% 25.35
Last Price 22.36
Fibonacci 38.2% 20.81
52-Week Low 6.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.